Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

Steffen Böhm; Nhu Le; Michelle Lockley; Elly Brockbank; Asma Faruqi; Ian Said; Arjun Jeyarajah; Rekha Wuntakal; Blake Gilks; Naveena Singh

doi:10.1136/ijgc-2018-000092

Citation Tools

other Versions

View the most recent version of this article
You are currently viewing an earlier version of this article (March 31, 2021).

Original Article

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Böhm S, Le N, Lockley M, et al

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

International Journal of Gynecologic Cancer Published Online First: 25 January 2019. doi: 10.1136/ijgc-2018-000092

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password